Survivin在食管癌中的表达及其与bcl-2表达关系的相关研究

目的探讨Survivin在食管癌组织中的表达及其与bcl-2蛋白表达的相关性。方法应用免疫组织化学SP法,检测Survivin、bcl-2蛋白在68例食管癌组织和20例正常食管组织中的表达。结果Survivin蛋白在正常食管组织中低表达或不表达,68例食管癌组织中,49例表达阳性,占72.1%。Survivin蛋白表达与分化程度、淋巴结转移密切相关(P<0.05)。食管癌组织bcl-2蛋白表达阳性、阴性组中,Survivin蛋白阳性表达率分别为94.7%(36/38)和43.3%(13/30),两者比较,差异有统计学意义(P<0.05)。Survivin蛋白表达与bcl-2蛋白表达密切相关。结论Survivin在食管癌组织中表达上调,通过抑制细胞凋亡,在食管癌的发生中起到重要作用;凋亡相关基因bcl-2的上调与Survivin的表达可能在食管癌变中起协同作用。     

脑膜瘤组织中Survivin和PCNA的表达

目的 探讨Survivin和PCNA在脑膜瘤组织中的表达及临床意义。方法 采用免疫组织化学sP法检测97例脑膜瘤组织和18例正常脑膜组织中Survivin和PCNA的表达。结果 Survivin在正常脑膜和脑膜瘤组织中阳性表达率为0％和65．9％（64／97），差异具有显著性（P〈0．001）。Survivln表达阳性率在脑膜瘤Ⅱ级（85．7％）和Ⅰ级（51、7％）之间、Ⅲ级（93．8％）和Ⅰ级之间差异具有显著性（P〈0．001）。PCNA蛋白在正常脑膜和脑膜瘤组织中表达阳性率为0％和55．7％（54／97），差异具有显著性（P〈0．001）。PC—NA表达阳性率在脑膜瘤Ⅱ级（71．4％）和Ⅰ级（41、7％）之间，Ⅲ级（87．5％）同Ⅰ级之间差异具有显著性（P〈0．001）。Survivin与PCNA蛋白在脑膜瘤中的表达呈正相关关系（rs=0．640，P〈0．01）。结论 Survivin过度表达和脑膜瘤发生及PCNA的表达密切相关，两者参与了脑膜瘤发生、增殖和发展。     

Characterization of cell death events induced by anti-neoplastic drugs cisplatin, paclitaxel and 5-fluorouracil on human hepatoma cell lines: Possible mechanisms of cell resistance.

Two different hepatoma cell lines were incubated for 48h with chemotherapeutic drugs cisplatin, paclitaxel and 5-FU to determine their ability to induce cytotoxicity and DNA fragmentation as well as to modify the expression of some cell death-related genes that could be involved in the resistance to therapy. We observed that cisplatin and paclitaxel induced cytotoxicity, but significant differences between both cell lines, were found only in the case of paclitaxel. At 48h, apoptosis was clearly present in Hep3B cells treated with cisplatin and HepG2 cells treated with paclitaxel. 5-FU induced cytotoxicity in both cell lines but only at higher concentrations than the other two drugs, triggering apoptosis and necrosis in HepG2 cells and only necrosis in Hep3B. When a time course was performed for the first 8h of treatment to elucidate the initial mechanism of cell death responsible for DNA fragmentation, we observed that 5-FU in Hep3B, and cisplatin in both cell lines, induces primary necrosis, whereas at the concentration tested here, paclitaxel clearly triggers apoptosis in both cell lines. HepG2 cells were weakly sensitive to 5-FU in the first 8h of treatment, so the primary mechanism of cell death was not clear, but results seem to indicate that it could be apoptosis. At 48h, Bax was not up-regulated with any of the treatments, whereas cisplatin was able to induce Bcl-xL down-regulation in both cell lines. Treatment with 5-FU also down-regulated Bcl-xL in HepG2 cells. We also measured variations in the expression of survivin, an inhibitor of apoptosis that has also been involved in mitototic catastrophe. Hep3B cells seem to show an increase in protein levels with all treatments. Exposure to paclitaxel resulted in the highest effect. In the case of HepG2 cells, there was a decrease in survivin expression when cells were treated with 5FU and paclitaxel, both treatments showing complete loss of the protein. Using an antibody that recognizes unprocessed caspase-3, we observed that the enzyme was assumingly activated in HepG2 cells treated with 5FU and paclitaxel, but only weakly after treatment with cisplatin. Hep3B cells did not show activation since the levels of the pro-enzyme remained the same as that in the control. In conclusion, the three drugs tested in this study could induce cell death, with paclitaxel being more effective inducing apoptosis. 5FU was only effective at high doses and its mechanism seems to be primarily related to necrosis in Hep3B and probably apoptosis in HepG2. Cisplatin mechanism of cell death is probably mediated by the decrease in anti-apoptotic protein Bcl-xL whereas paclitaxel and 5FU are decreasing the apoptosis inhibitor survivin. According to pro-enzyme levels, caspase-3 was only activated in HepG2 cells, whereas in the case of Hep3B cells the mechanisms of toxicity appear to be caspase-3-independent at the time and concentrations tested in this study. The resistance of Hep3B cells to death induced by chemotherapy could be related to an increase in the expression of IAP survivin, which can decrease cell response to the treatment or even switch the type of death from apoptosis to another kind, making therapy less efficient.     

survivin与nmp22对诊断尿路上皮肿瘤价值的比较

目的 :评价尿脱落细胞中survivin的表达和尿nmp2 2的表达对诊断尿路上皮肿瘤的价值。 方法 :对4 8例尿路上皮肿瘤患者 ,在行膀胱镜检查或手术前留新鲜尿液分别行尿脱落细胞survivin、尿nmp2 2和尿脱落细胞检查 ,并分别比较各方法的敏感性、特异性。结果 :尿路上皮肿瘤患者尿脱落细胞涂片中survivin表达 4 8例中4 6例阳性 ,尿NMP2 2有 38例阳性 ,而尿脱落细胞学仅 15例阳性 ,survivin的敏感性高于nmp2 2及脱落细胞学 (P <0 .0 5及P <0 .0 1)。三者的特异性分别为 10 0 %、90 %和 10 0 % ,差异无统计学意义。结论 :检测尿脱落细胞中survivin的表达方法简单无创敏感性、特异性高对诊断尿路上皮肿瘤的价值优于尿nmp2 2。     

生存素在恶性肿瘤诊治中的应用研究进展

生存素(Survivin)是凋亡抑制蛋白(IAP)家族的新近成员,表达于胚胎组织和多种癌组织,在大多数终末分化的正常组织中未能检测出表达。Survivin的表达受细胞周期调控,在G2/M期有异常高的特异性表达。由于其独特的结构、特殊的组织分布及在细胞凋亡和细胞分裂调控中所起作用,引起了肿瘤研究工作者的浓厚兴趣,现将Survivin在恶性肿瘤诊治方面的研究进展作一综述。1 Survivin的生物学特性Survivin是1997年Altieri利用效应细胞蛋白酶受体1(effector cell protease receptor 1,EPR)筛选cDNA人基因组库获得的凋亡抑制蛋白。Survivin基因全长1…     

紫杉醇诱导胰腺癌细胞凋亡Survivin表达的变化及意义

目的研究紫杉醇（PA）体外化疗对胰腺癌细胞凋亡抑制蛋白Survivin基因表达的影响。方法培养人胰腺癌细胞株SW1990，加入低浓度的PA，用流式细胞仪分别检测加药前和加药后24、48h的细胞凋亡率，用逆转录-聚合酶链反应（RT-PCR）和免疫印迹技术（Western blot）检测Survivin mRNA和蛋白的表达。结果SW1990细胞给予低浓度的PA后，加药前和加药后24、48h的细胞凋亡率分别为（2．59±0．35）％、（14．75±1．29）％、（22．65±2．80）％；其Survivin mRNA的表达则分别比加药前提高了1．1倍和2．9倍；Survivin蛋白的表达分别增加了1．3倍和3．6倍。结论应用PA化疗可促使胰腺癌细胞内Survivin表达的增加，抵抗化疗诱导的细胞凋亡。     

检测膀胱肿瘤Survivin蛋白及其mRNA表达的临床意义

目的为明确Survivin作为膀胱肿瘤患者的肿瘤诊断和监测标志物的可能性,我们检测了Survivin在膀胱肿瘤和非肿瘤患者病变组织的Survivin蛋白及其mRNA表达情况。方法从我科住院病人和膀胱镜检患者中获取31例膀胱癌患者(实验组)和24例非肿瘤患者(对照组)的组织标本,用免疫组织化学法(IHC)和RT-PCR检测Survivin蛋白和基因在肿瘤组织和非肿瘤组织中的表达情况。并对结果行相应的统计学分析。结果IHC检测实验组和对照组Survivin蛋白的阳性率分别为74%(23/31)和4%(1/24),χ2检验P<0.001,IHC的阳性率与肿瘤的分级分期有一定的关系;实验组和对照组RT-PCR检测Survivin mRNA的表达阳性率分别为90%(30/31)和4%(1/24),χ2检验P<0.001。结论膀胱肿瘤组织Survivin蛋白和基因的表达量高于对照组,因此,Survivin有望成为膀胱瘤高危人群筛选,肿瘤诊断和监测的工具之一。     

Survivin反义核酸对SMMC-7721细胞增殖和凋亡的影响

Survivin是凋亡抑制蛋白（IAP）家族的一个成员，具有强大的抗细胞凋亡功能，在几乎所有肿瘤组织中特异性表达，而在正常成年终末分化组织中低表达甚至不表达。本研究针对Survivin mRNA序列设计了反义寡核甘酸，RT—PCR检测表明，该序列反义寡核苷酸可明显降低细胞中survivin基因的mRNA含量；Western印迹显示Survivin蛋白水平也被降低。MTT比色实验法检测结果说明人Survivin反义寡核苷酸抑制SMMC-7721细胞增殖，抑制率为43％，远高于无义寡核苷酸组和空白对照组。反义寡核苷酸还显著增强SMMC-7721细胞对于抗肿瘤药高三尖杉酯碱的敏感性，TUNEL法检测结果显示，在较低高三尖杉酯碱浓度下，反义寡核苷酸转染细胞的凋亡率明显高于其它对照组。本研究结果提示，survivin表达的靶向抑制有望应用于肿瘤的辅助治疗之中。     

Hela细胞Survivin克隆及HLA-A2限制性CTL表位预测研究

目的：从Hela细胞中克隆凋亡抑制因子Survivin的编码序列,进行测序,并由此预测其HLA-A＊0201限制性CTL表位。方法：设计人Survivin基因序列特异引物,通过RT-PCR扩增Survivin编码序列,构建至pGEM-T载体后,测序分析,并对其进行了HLA-A＊0201限制性CTL表位抗原表位相关预测。结果：从Hela细胞中克隆得到的Survivin和Survivin-ΔEx3两种剪接体,其中Survivin-ΔEx3发生1个同义突变和三个错义突变,预测其抗原表位抗原性发生了变化。结论：寻找抗原性强、结合力高的表位,对于今后抗肿瘤多肽疫苗的研究具有重要的意义。     

癌基因c-fos、c-jun、Survivin及p63蛋白在皮肤鳞状细胞癌中的表达及意义

目的 研究皮肤鳞癌组织中癌基因c-fos、c-jun、Survivin和p63蛋白的表达及其意义。 方法 采用免疫组化法检测60例皮肤鳞癌组织中c-fos、c-jun、Survivin和p63蛋白的表达,探讨与鳞癌组织分化程度的关系。结果 (1)c-fos、c-jun在皮肤鳞癌中的表达阳性率分别为61.7%和48.3%,其表达水平与癌组织的分化程度有关(P<0.05),肿瘤的分化程度越高其表达水平越高。(2)Survivin蛋白在皮肤鳞癌组织中阳性表达率为73.3%,其表达越强,组织分化程度越低。(3)p63在高分化鳞癌中呈环状分布于癌巢周围,低分化鳞癌中阳性细胞增多,分布紊乱,其表达在癌的不同分化中有显著性差异。结论 c-fos、c-jun的表达水平可作为判定皮肤鳞癌分化的指标,可作为皮肤鳞癌的生物学标记物。Survivin蛋白的表达与分化程度有密切关系,它的高表达提示肿瘤预后不良,也可能成为治疗皮肤鳞癌的重要新靶点。p63过度表达的癌细胞是获得了更具增殖、侵袭和间变能力的细胞。